Compare Eli Lilly And Co (LLY) vs Liquidia Corporation Common Stock (LQDA) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Eli Lilly And Co vs Liquidia Corporation Common Stock — how do they compare? Eli Lilly And Co trades at $1,228.47 (market cap $1.08T), while Liquidia Corporation Common Stock trades at $33.9 (market cap $3.04B). The key difference: Eli Lilly And Co is far larger — about 355.3× Liquidia Corporation Common Stock's market cap, and Eli Lilly And Co pays a 0.57% dividend while Liquidia Corporation Common Stock pays none. Which is the better fit depends on your goals — on Pluang, investors hold Eli Lilly And Co for 94 Days and Liquidia Corporation Common Stock for 0 Days on average.
| LLY | LQDA | |
|---|---|---|
Market Cap | $1.08T | $3.04B |
Volume | 2,520,401 | 21,111,778 |
Sector | Health | Health |
52-Week High | $1.28K | $91.03 |
52-Week Low | $799.57 | $22.02 |
Typical Hold Time | 94 Days | 0 Days |
Enterprise Value | $1.12T | $2.94B |
Dividend Yield | 0.57% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Eli Lilly (LLY) trades at $1,166.51, down 1.36% on the day, amid a bullish technical outlook with strong fundamental performance. The company reported robust earnings beats in recent quarters, with Q2 2026 EPS of $8.38 surpassing the $6.40 estimate. Revenue surged to $65.18 billion in 2025, driving a net income margin of 33.53%. Positive news flow highlights advancements in weight-loss and diabetes drugs, reinforcing growth prospects.
LLY's outlook remains positive, supported by a dominant position in obesity treatments and a promising pipeline. Risks include competitive pressures and high valuation multiples. Analyst consensus is strongly bullish with a $1,350 price target, though investors should monitor execution and regulatory developments.
No Aura AI signal available yet.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Eli Lilly And Co
Eli Lilly is a drug firm with a focus on neuroscience, endocrinology, cancer, and immunology. Lilly's key products include Verzenio for cancer
Read more on LLY →About Liquidia Corporation Common Stock
Liquidia Corporation is a biopharmaceutical company that develops therapies for rare cardiopulmonary diseases, including YUTREPIA, an inhaled treprostinil powder for pulmonary hypertension built on its PRINT technology.
Read more on LQDA →
